Contrasting Curaleaf (CURLF) and Its Competitors

Curaleaf (OTCMKTS:CURLFGet Rating) is one of 57 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it contrast to its competitors? We will compare Curaleaf to related businesses based on the strength of its earnings, profitability, institutional ownership, dividends, risk, valuation and analyst recommendations.

Earnings and Valuation

This table compares Curaleaf and its competitors revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Curaleaf $1.21 billion -$101.73 million -35.11
Curaleaf Competitors $265.37 million -$99.14 million -10.64

Curaleaf has higher revenue, but lower earnings than its competitors. Curaleaf is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Curaleaf and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Curaleaf -9.72% -7.08% -3.70%
Curaleaf Competitors 470.52% -7.30% 112.92%

Analyst Recommendations

This is a summary of current ratings and target prices for Curaleaf and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Curaleaf 0 1 7 0 2.88
Curaleaf Competitors 188 527 721 41 2.42

Curaleaf presently has a consensus price target of $12.25, indicating a potential upside of 93.83%. As a group, “Medicinals & botanicals” companies have a potential upside of 145.23%. Given Curaleaf’s competitors higher possible upside, analysts clearly believe Curaleaf has less favorable growth aspects than its competitors.

Institutional & Insider Ownership

14.5% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 27.0% of shares of all “Medicinals & botanicals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Curaleaf competitors beat Curaleaf on 8 of the 12 factors compared.

Curaleaf Company Profile

(Get Rating)

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates in two segments, Cannabis Operations and Non-Cannabis Operations. The Cannabis Operations segment engages in the production and sale of cannabis through retail and wholesale channels. The Non-Cannabis Operations segment provides professional services, including cultivation, processing, and retail know-how and back-office administration, intellectual property licensing, real estate leasing services, and lending facilities to medical and adult-use cannabis licensees under management service agreements. It offers flowers, pre-rolls, flower pods, and dry-herb vaporizer cartridges; concentrates for vaporizing, such as pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, including distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles. The company also provides hemp-based CBD products. As of June 16, 2022, it operated 134 dispensaries and 26 cultivation sites in 22 states of the United States. The company was founded in 2010 and is headquartered in Wakefield, Massachusetts.

Receive News & Ratings for Curaleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curaleaf and related companies with MarketBeat.com's FREE daily email newsletter.